Sofinnova MD Start III

DGAP-News: Gradient Denervation Technologies Raises €3.5M in Seed Funding with Sofinnova Partners

Retrieved on: 
Thursday, September 17, 2020
Medicine, Clinical medicine, Hypertension, Sofinnova, Medical specialties, Medical terminology, Denervation, Minimally invasive procedure, Pulmonary hypertension, Interventional radiology, Renal sympathetic denervation, Gradient Denervation Technologies, Sofinnova Partners, Sofinnova MD Start III

PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.

Key Points: 
  • PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.
  • Founded in February 2020, Gradient Denervation Technologies ("Gradient") builds on an innovation from two clinicians from Stanford University, Dr. Swami Gnanashanmugam and Dr. Jeffrey Feinstein.
  • Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology developed by two clinicians from Stanford University.
  • It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France.

DGAP-News: MastOR Secures Seed Funding from Sofinnova Partners to Develop its Laparoscopy Assistance Platform

Retrieved on: 
Thursday, July 2, 2020
Medicine, Clinical medicine, Endoscopy, Surgery, Laparoscopy, Minimally invasive procedure, Sofinnova, Robot-assisted surgery, MastOR, Sofinnova Partners, Sofinnova MD Start III

The funding will be used to advance MastOR's laparoscopy assistance platform, which broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

Key Points: 
  • The funding will be used to advance MastOR's laparoscopy assistance platform, which broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.
  • MastOR leverages the power of surgical robotics and existing laparoscopy instruments to offer a ubiquitous, affordable and modular platform delivering pristine surgical assistance in minimally-invasive digestive procedures.
  • MastOR SAS is a Paris-based, early stage medical device company, developing a surgical robot for laparoscopy assistance.
  • Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies.